Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study

P. A. Ho; T. A. Alonzo; K. J. Kopecky; K. L. Miller; J. Kuhn; R. Zeng; R. B. Gerbing; S. C. Raimondi; B. A. Hirsch; V. Oehler; C. A. Hurwitz; J. L. Franklin; A. S. Gamis; S. H. Petersdorf; J. E. Anderson; G. H. Reaman; L. H. Baker; C. L. Willman; I. D. Bernstein; J. P. Radich; F. R. Appelbaum; D. L. Stirewalt; S. Meshinchi

doi:10.1038/leu.2010.56

Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study

P. A. Ho, T. A. Alonzo, K. J. Kopecky, K. L. Miller, J. Kuhn, R. Zeng, R. B. Gerbing, S. C. Raimondi, B. A. Hirsch, V. Oehler, C. A. Hurwitz, J. L. Franklin, A. S. Gamis, S. H. Petersdorf, J. E. Anderson, G. H. Reaman, L. H. Baker, C. L. Willman, I. D. Bernstein, J. P. RadichF. R. Appelbaum, D. L. Stirewalt, S. Meshinchi

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

Recent whole-genome sequencing efforts led to the identification of IDH1^R132 mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children's Oncology Group trial COG-AAML03P1 (N=257), and Southwest Oncology Group trials SWOG-9031, SWOG-9333 and SWOG-9500 (N=274), were tested for IDH1 mutations. Codon R132 mutations were absent in the pediatric cohort, but were found in 12 of 274 adult patients (4.4%, 95% CI 2.3-7.5). IDH1 R132 mutations occurred most commonly in patients with normal karyotype, and those with FLT3/ITD and NPMc mutations. Patients with IDH1 R132 mutations trended toward higher median diagnostic white blood cell counts (59.2 × 10⁹ vs 29.1 × 10⁹ per liter, P=0.19) than those without mutations, but the two groups did not differ significantly in age, bone marrow blast percentage, overall survival or relapse-free survival. Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML.

Original language	English (US)
Pages (from-to)	909-913
Number of pages	5
Journal	Leukemia
Volume	24
Issue number	5
DOIs	https://doi.org/10.1038/leu.2010.56
State	Published - May 2010

Bibliographical note

Funding Information:
We thank the patients and families who consented to the use of biologic specimens in these trials. We also thank the AML Reference Laboratories of the COG and SWOG for providing diagnostic specimens, and Dr Cherise Guess for scientific editing. This work was supported by the National Institutes of Health (Grants No. K23 CA92405, CA18029, CA32102, CA114563, R01 CA114563-01, R21 CA102624, R21 CA10262-01, U10 CA032102-30, CA38926, CA20319, CA27057, CA12213 and Children’s Oncology Group Chair’s Grant NIH U10 CA98543).

Keywords

Acute myeloid leukemia
FLT3
IDH1
Isocitrate dehydrogenase
NPM
Pediatric AML

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/leu.2010.56

OpenUrl availability

Full text

Cite this

Ho, P. A., Alonzo, T. A., Kopecky, K. J., Miller, K. L., Kuhn, J., Zeng, R., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Oehler, V., Hurwitz, C. A., Franklin, J. L., Gamis, A. S., Petersdorf, S. H., Anderson, J. E., Reaman, G. H., Baker, L. H., Willman, C. L., Bernstein, I. D., ... Meshinchi, S. (2010). Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study. Leukemia, 24(5), 909-913. https://doi.org/10.1038/leu.2010.56

Ho, PA, Alonzo, TA, Kopecky, KJ, Miller, KL, Kuhn, J, Zeng, R, Gerbing, RB, Raimondi, SC, Hirsch, BA, Oehler, V, Hurwitz, CA, Franklin, JL, Gamis, AS, Petersdorf, SH, Anderson, JE, Reaman, GH, Baker, LH, Willman, CL, Bernstein, ID, Radich, JP, Appelbaum, FR, Stirewalt, DL & Meshinchi, S 2010, 'Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study', Leukemia, vol. 24, no. 5, pp. 909-913. https://doi.org/10.1038/leu.2010.56

@article{69098676eb7848ea8540be99616536a2,

title = "Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study",

abstract = "Recent whole-genome sequencing efforts led to the identification of IDH1R132 mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children's Oncology Group trial COG-AAML03P1 (N=257), and Southwest Oncology Group trials SWOG-9031, SWOG-9333 and SWOG-9500 (N=274), were tested for IDH1 mutations. Codon R132 mutations were absent in the pediatric cohort, but were found in 12 of 274 adult patients (4.4%, 95% CI 2.3-7.5). IDH1 R132 mutations occurred most commonly in patients with normal karyotype, and those with FLT3/ITD and NPMc mutations. Patients with IDH1 R132 mutations trended toward higher median diagnostic white blood cell counts (59.2 × 109 vs 29.1 × 109 per liter, P=0.19) than those without mutations, but the two groups did not differ significantly in age, bone marrow blast percentage, overall survival or relapse-free survival. Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML.",

keywords = "Acute myeloid leukemia, FLT3, IDH1, Isocitrate dehydrogenase, NPM, Pediatric AML",

author = "Ho, {P. A.} and Alonzo, {T. A.} and Kopecky, {K. J.} and Miller, {K. L.} and J. Kuhn and R. Zeng and Gerbing, {R. B.} and Raimondi, {S. C.} and Hirsch, {B. A.} and V. Oehler and Hurwitz, {C. A.} and Franklin, {J. L.} and Gamis, {A. S.} and Petersdorf, {S. H.} and Anderson, {J. E.} and Reaman, {G. H.} and Baker, {L. H.} and Willman, {C. L.} and Bernstein, {I. D.} and Radich, {J. P.} and Appelbaum, {F. R.} and Stirewalt, {D. L.} and S. Meshinchi",

note = "Funding Information: We thank the patients and families who consented to the use of biologic specimens in these trials. We also thank the AML Reference Laboratories of the COG and SWOG for providing diagnostic specimens, and Dr Cherise Guess for scientific editing. This work was supported by the National Institutes of Health (Grants No. K23 CA92405, CA18029, CA32102, CA114563, R01 CA114563-01, R21 CA102624, R21 CA10262-01, U10 CA032102-30, CA38926, CA20319, CA27057, CA12213 and Children{\textquoteright}s Oncology Group Chair{\textquoteright}s Grant NIH U10 CA98543).",

year = "2010",

month = may,

doi = "10.1038/leu.2010.56",

language = "English (US)",

volume = "24",

pages = "909--913",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Molecular alterations of the IDH1 gene in AML

T2 - A Children's Oncology Group and Southwest Oncology Group study

AU - Ho, P. A.

AU - Alonzo, T. A.

AU - Kopecky, K. J.

AU - Miller, K. L.

AU - Kuhn, J.

AU - Zeng, R.

AU - Gerbing, R. B.

AU - Raimondi, S. C.

AU - Hirsch, B. A.

AU - Oehler, V.

AU - Hurwitz, C. A.

AU - Franklin, J. L.

AU - Gamis, A. S.

AU - Petersdorf, S. H.

AU - Anderson, J. E.

AU - Reaman, G. H.

AU - Baker, L. H.

AU - Willman, C. L.

AU - Bernstein, I. D.

AU - Radich, J. P.

AU - Appelbaum, F. R.

AU - Stirewalt, D. L.

AU - Meshinchi, S.

N1 - Funding Information: We thank the patients and families who consented to the use of biologic specimens in these trials. We also thank the AML Reference Laboratories of the COG and SWOG for providing diagnostic specimens, and Dr Cherise Guess for scientific editing. This work was supported by the National Institutes of Health (Grants No. K23 CA92405, CA18029, CA32102, CA114563, R01 CA114563-01, R21 CA102624, R21 CA10262-01, U10 CA032102-30, CA38926, CA20319, CA27057, CA12213 and Children’s Oncology Group Chair’s Grant NIH U10 CA98543).

PY - 2010/5

Y1 - 2010/5

N2 - Recent whole-genome sequencing efforts led to the identification of IDH1R132 mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children's Oncology Group trial COG-AAML03P1 (N=257), and Southwest Oncology Group trials SWOG-9031, SWOG-9333 and SWOG-9500 (N=274), were tested for IDH1 mutations. Codon R132 mutations were absent in the pediatric cohort, but were found in 12 of 274 adult patients (4.4%, 95% CI 2.3-7.5). IDH1 R132 mutations occurred most commonly in patients with normal karyotype, and those with FLT3/ITD and NPMc mutations. Patients with IDH1 R132 mutations trended toward higher median diagnostic white blood cell counts (59.2 × 109 vs 29.1 × 109 per liter, P=0.19) than those without mutations, but the two groups did not differ significantly in age, bone marrow blast percentage, overall survival or relapse-free survival. Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML.

AB - Recent whole-genome sequencing efforts led to the identification of IDH1R132 mutations in acute myeloid leukemia (AML) patients. We studied the prevalence and clinical implications of IDH1 genomic alterations in pediatric and adult AML. Diagnostic DNA from 531 AML patients treated on Children's Oncology Group trial COG-AAML03P1 (N=257), and Southwest Oncology Group trials SWOG-9031, SWOG-9333 and SWOG-9500 (N=274), were tested for IDH1 mutations. Codon R132 mutations were absent in the pediatric cohort, but were found in 12 of 274 adult patients (4.4%, 95% CI 2.3-7.5). IDH1 R132 mutations occurred most commonly in patients with normal karyotype, and those with FLT3/ITD and NPMc mutations. Patients with IDH1 R132 mutations trended toward higher median diagnostic white blood cell counts (59.2 × 109 vs 29.1 × 109 per liter, P=0.19) than those without mutations, but the two groups did not differ significantly in age, bone marrow blast percentage, overall survival or relapse-free survival. Eleven patients (2.1%) harbored a novel V71I sequence alteration, which was found to be a germ-line polymorphism. IDH1 mutations were not detected in pediatric AML, and are uncommon in adult AML.

KW - Acute myeloid leukemia

KW - FLT3

KW - IDH1

KW - Isocitrate dehydrogenase

KW - NPM

KW - Pediatric AML

UR - http://www.scopus.com/inward/record.url?scp=77952424259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952424259&partnerID=8YFLogxK

U2 - 10.1038/leu.2010.56

DO - 10.1038/leu.2010.56

M3 - Article

C2 - 20376086

AN - SCOPUS:77952424259

SN - 0887-6924

VL - 24

SP - 909

EP - 913

JO - Leukemia

JF - Leukemia

IS - 5

ER -

Molecular alterations of the IDH1 gene in AML: A Children's Oncology Group and Southwest Oncology Group study

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this